RxDoctor Payments Data

Carl Johnson, MD

Family Medicine · Tifton, GANPI 1023018561

Payments from drug & device makers

$5,757in general payments, 2019–2025

Across 335 payments — averaging $17.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$705
  • AstraZeneca$693
  • GSK$523
  • Novo Nordisk$457
  • Amgen$442
  • Lilly USA, LLC$381
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$5,757100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,757 in reported general payments places this provider in the 85th percentile of 3,111 family medicine providers in Georgia.

See all family medicine providers in Georgia

Medicare billing

Part B allowed, 2024
$90,446
Medicare patients
368
Services billed
9,897

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide93$105,669
MounjaroTirzepatide52$59,590
FarxigaDapagliflozin Propanediol54$58,949
OzempicSemaglutide50$53,713
EliquisApixaban55$47,280
JardianceEmpagliflozin33$35,366
XareltoRivaroxaban19$22,319
MyrbetriqMirabegron41$21,868
Trelegy ElliptaFluticasone/Umeclidin/Vilanter16$16,505
JanuviaSitagliptin Phosphate13$15,351
ShingrixVaricella-Zoster Ge/As01b/Pf52$11,535
LinzessLinaclotide18$10,978
Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/718$9,324
Levemir FlexpenInsulin Detemir31$5,732
SymbicortBudesonide/Formoterol Fumarate25$5,312

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$381$165,259145 claims
AstraZenecaFarxiga, Symbicort$693$64,26279 claims
Novo NordiskOzempic$457$53,71350 claims
PfizerEliquis$355$47,28055 claims
Boehringer IngelheimJardiance$98$35,36633 claims
GSKTrelegy Ellipta, Shingrix$523$28,04068 claims
Johnson & JohnsonXarelto$192$22,31919 claims
Astellas Pharma US IncMyrbetriq$115$21,86841 claims
MerckJanuvia$27$15,35113 claims
AbbVieLinzess, Synthroid$705$14,20764 claims
Sanofi-aventis U.S. LLCLantus$32$2,05318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 3,111 family medicine providers in Georgia.

Other family medicine in Tifton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →